National Cancer Center, Japan
Clinical trials sponsored by National Cancer Center, Japan, explained in plain language.
-
Can a targeted drug shrink Hard-to-Treat thymic tumors?
Disease control Not yet recruitingThis phase II trial is testing whether an experimental drug called sacituzumab tirumotecan (Sac-TMT) can shrink tumors in people with thymic carcinoma that cannot be surgically removed and has already been treated with platinum-based chemotherapy. Participants receive the drug in…
Phase: PHASE2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a TROP2-targeting drug shrink hard-to-treat small bowel cancer?
Disease control Not yet recruitingThis phase II trial tests whether sacituzumab tirumotecan, an antibody-drug conjugate that targets the TROP2 protein, can shrink tumors in people with advanced small bowel adenocarcinoma that has worsened after platinum-based chemotherapy. About 27 adults with this rare cancer wi…
Phase: PHASE2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC